# QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors

> **NCT05108779** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Tumor

## Interventions

- **DRUG:** QLF32004

## Key facts

- **NCT ID:** NCT05108779
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-09
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05108779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05108779, "QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05108779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*